16 – 30 of 72
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
COMP a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker
(
- Contribution to journal › Article
- 2007
-
Mark
Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials
(
- Contribution to journal › Article
- 2006
-
Mark
The heritable determinants of cartilage oligomeric matrix protein
(
- Contribution to journal › Article
-
Mark
Classification of osteoarthritis biomarkers: a proposed approach
(
- Contribution to journal › Scientific review
-
Mark
Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis
(
- Contribution to journal › Article
-
Mark
Biomarkers for cartilage and bone in rheumatoid arthritis
2006) p.301-301(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Non-collagenous Proteins; Glycoproteins and related proteins
2006) p.71-84(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Serum levels of Cartilage Oligomeric Matrix Protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis
(
- Contribution to journal › Article
-
Mark
Noncollagenous Proteins: Glycoproteins and Related Proteins
2006) p.71-84(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2005
-
Mark
Prognostic laboratory markers of joint damage in rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Matrix Glycoproteins and Proteoglycans in Cartilage
(
- Chapter in Book/Report/Conference proceeding › Book chapter
- 2004
-
Mark
Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures.
(
- Contribution to journal › Article
- 2003
-
Mark
Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
(
- Contribution to journal › Article
-
Mark
Recent developments and future research in the bone and joint decade 2000-2010.
(
- Contribution to journal › Letter
-
Mark
Inflammation is a feature of the disease process in early knee joint osteoarthritis.
(
- Contribution to journal › Letter